# Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma

> **NCT05050461** · NA · TERMINATED · sponsor: **Versailles Hospital** · enrollment: 120 (actual)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell
- Vaccination Failure

## Interventions

- **OTHER:** Immunological analyses

## Key facts

- **NCT ID:** NCT05050461
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-15
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-11-15
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** Given the evolution of Covid 19, patient inclusions became very difficult or even non-existent in all participating centers over time
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050461, "Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05050461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*